Castle Biosciences (CSTL) Income towards Parent Company (2018 - 2025)
Historic Income towards Parent Company for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$501000.0.
- Castle Biosciences' Income towards Parent Company fell 12208.02% to -$501000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 30085.6%. This contributed to the annual value of $18.2 million for FY2024, which is 13174.92% up from last year.
- Latest data reveals that Castle Biosciences reported Income towards Parent Company of -$501000.0 as of Q3 2025, which was down 12208.02% from $4.6 million recorded in Q2 2025.
- Castle Biosciences' 5-year Income towards Parent Company high stood at $9.6 million for Q4 2024, and its period low was -$29.2 million during Q1 2023.
- Moreover, its 5-year median value for Income towards Parent Company was -$6.4 million (2021), whereas its average is -$8.4 million.
- As far as peak fluctuations go, Castle Biosciences' Income towards Parent Company plummeted by 103938.11% in 2023, and later soared by 47170.54% in 2024.
- Over the past 5 years, Castle Biosciences' Income towards Parent Company (Quarter) stood at -$6.4 million in 2021, then plummeted by 220.65% to -$20.6 million in 2022, then soared by 87.49% to -$2.6 million in 2023, then surged by 471.71% to $9.6 million in 2024, then tumbled by 105.22% to -$501000.0 in 2025.
- Its Income towards Parent Company was -$501000.0 in Q3 2025, compared to $4.6 million in Q2 2025 and -$25.8 million in Q1 2025.